VX-478 oral protease inhibitor: Partner Glaxo Wellcome began a Phase I/II dose-ranging trial in the U.S. and Europe testing 300 mg twice or three times daily an

Vertex Pharmaceuticals Inc. (VRTX), Cambridge, Mass. Product: VX-478 oral protease inhibitor Indication: HIV Status: Partner Glaxo Wellcome began a Phase I/II dose-ranging trial in the U.S. and Europ...